JIA-HORNG KAOCHUN-JEN LIUDING-SHINN CHEN2021-09-042021-09-0420020168-8278https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036171680&doi=10.1016%2fS0168-8278%2801%2900246-X&partnerID=40&md5=d8eeb756733a09aa174a7bb730016639https://scholars.lib.ntu.edu.tw/handle/123456789/582254[SDGs]SDG3alpha interferon; lamivudine; adult; clinical article; controlled study; disease association; dose response; female; genotype; hepatitis B; Hepatitis B virus; human; letter; liver carcinoma; liver cirrhosis; male; priority journal; risk factor; serology; virus resistance; Adult; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitorsletter10.1016/S0168-8278(01)00246-X118303462-s2.0-0036171680